New HealthTech fund highlights growth capital pathway for SMEs
A new Apposite Capital fund, backed by the British Business Bank, points to the importance of investment support for HealthTech companies moving from development into scale-up.
HealthTech companies often begin with a strong idea, a clear clinical need and early evidence that their product or platform has potential. However, moving from development into commercial growth usually requires more than technical progress.
A recent funding update shared by SEHTA highlights a new Apposite Capital growth fund, supported by a £100m commitment from the British Business Bank. SEHTA notes that the fund is expected to attract double or triple that amount in additional investment.
The announcement is relevant for HealthTech and MedTech SMEs because it points to one of the most important stages in the innovation journey: the move from early development into scale-up.
Early-stage support can help companies test ideas, develop prototypes and build initial evidence. Growth capital plays a different role. It can help companies strengthen teams, prepare for regulation, develop commercial partnerships, build market access and move closer to wider adoption.
This is particularly important in healthcare, where products often need stronger evidence, longer development timelines and clearer routes to market than many other technology sectors. A promising product may still need investment in clinical validation, quality systems, regulatory planning, manufacturing readiness or customer engagement before it can scale.
SEHTA, the South East Health Technologies Alliance, supports health technology companies by connecting them with funding, advice, networks and market opportunities. By sharing funding opportunities like this, SEHTA helps make the investment landscape more visible for companies working across HealthTech, MedTech and related sectors.
For SMEs, the message is clear: investment readiness is part of innovation readiness. Companies need to think not only about what they are building, but how they will evidence it, commercialise it and scale it.
The Apposite Capital fund is a useful reminder that HealthTech innovation needs more than good ideas. It needs the right support, at the right stage, to help companies move from early promise into real market opportunity.
Original article